Literature DB >> 17403258

Toenail onychomycosis: current and future treatment options.

Justin J Finch1, Erin M Warshaw.   

Abstract

Onychomycosis is a common disease affecting as much as 8% of the general population. Treatment of onychomycosis is challenging, complicated by low cure rates and relatively high relapse rates. This paper reviews the efficacy of current oral, topical, and surgical treatment options. Currently, the treatment of choice for toenail onychomycosis is oral terbinafine because of its high efficacy, low relapse rates, and cost-effectiveness. Oral itraconazole or fluconazole could be considered for infections caused by Candida. Topical therapies may be a useful adjunct to these systemic therapies, but are less effective when used alone. More research is needed to determine the best measures for preventing reinfection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403258     DOI: 10.1111/j.1529-8019.2007.00109.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  19 in total

Review 1.  Skin conditions in figure skaters, ice-hockey players and speed skaters: part II - cold-induced, infectious and inflammatory dermatoses.

Authors:  Brook E Tlougan; Anthony J Mancini; Jenny A Mandell; David E Cohen; Miguel R Sanchez
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

2.  An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafine.

Authors:  Anroop B Nair; Hyun D Kim; Shawn P Davis; Robert Etheredge; Michael Barsness; Phillip M Friden; S Narasimha Murthy
Journal:  Pharm Res       Date:  2009-07-07       Impact factor: 4.200

Review 3.  Essential Oils for Treatment for Onychomycosis: A Mini-Review.

Authors:  Fernanda C Flores; Ruy C R Beck; Cristiane de B da Silva
Journal:  Mycopathologia       Date:  2015-10-19       Impact factor: 2.574

4.  Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis.

Authors:  T Jones; A Tavakkol
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 5.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.

Authors:  Alessandro Subissi; Daniela Monti; Giuseppe Togni; Federico Mailland
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

6.  Laser irradiation on growth of trichophyton rubrum: an in vitro study.

Authors:  Seyed Alireza Ghavam; Saeed Aref; Ezedin Mohajerani; Mohammad Reza Shidfar; Hamideh Moravvej
Journal:  J Lasers Med Sci       Date:  2015

7.  Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.

Authors:  William J Jo Siu; Yoshiyuki Tatsumi; Hisato Senda; Radhakrishnan Pillai; Takashi Nakamura; Daisuke Sone; Annette Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

Review 8.  Update in antifungal therapy of dermatophytosis.

Authors:  Aditya K Gupta; Elizabeth A Cooper
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

9.  Ultraviolet C inactivation of dermatophytes: implications for treatment of onychomycosis.

Authors:  T Dai; G P Tegos; G Rolz-Cruz; W E Cumbie; M R Hamblin
Journal:  Br J Dermatol       Date:  2008-04-10       Impact factor: 9.302

10.  Iontophoretically enhanced ciclopirox delivery into and across human nail plate.

Authors:  Jinsong Hao; Kelly A Smith; S Kevin Li
Journal:  J Pharm Sci       Date:  2009-10       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.